BRAF and MEK inhibitor combinations (BRAF/MEKi) have significantly improved survival in melanoma patients with BRAF mutations, but can induce a wide spectrum of cardiovascular (CV) toxicities. This evidence concerns the gene MAP2K7 and melanoma.